BD Merges Biosciences & Diagnostics Business With Waters

February 11, 2026 - 20:42

In a major strategic shift, BD (Becton, Dickinson and Company) has finalized the separation and merger of its Biosciences and Diagnostic Systems units with Waters Corporation. The completed transaction marks BD's decisive pivot toward becoming a pure-play medical technology company.

The complex deal involved spinning off the combined entity, now an independent publicly traded company, which subsequently merged with Waters. This move allows BD to streamline its operations and concentrate its resources entirely on its core medical device and technology portfolio. The company has secured approximately $4 billion in gross cash proceeds from the transaction, providing significant financial flexibility.

Industry analysts view this restructuring as a focused strategy to enhance innovation and growth within BD's remaining medical technology segments, which include medication delivery, pharmaceutical systems, and surgical instruments. The company leadership stated the move strengthens their ability to address critical healthcare challenges and drive long-term value by dedicating full attention to high-growth medtech markets. The completion of this transaction signifies a new chapter for BD as a more specialized entity in the global healthcare landscape.